ArticleUrology2010
ERG rearrangement metastasis patterns in locally advanced prostate cancer.
Article in Urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 57 citations in OpenAlex.
- TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers.PloS one · 2014Trial
- Exploring the efficacy of AMACR, ERG, and AR immunostains in prostatic adenocarcinoma and their association with novel grade groups.European journal of histochemistry : EJH · 2025Article
- The evolving landscape of prostate cancer somatic mutations.The Prostate · 2022Review
- Article
- The Genomics of Prostate Cancer: A Historic Perspective.Cold Spring Harbor perspectives in medicine · 2019Review
- Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.European urology focus · 2018Article
- High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases.Oncology letters · 2018Article
- Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay.The Journal of molecular diagnostics : JMD · 2017Article
- TMPRSS2-ERG fusion promotes prostate cancer metastases in bone.Oncotarget · 2017Article
- Landscape of gene fusions in epithelial cancers: seq and ye shall find.Genome medicine · 2015Review
- TMPRSS2-ERG fusion transcripts expression in patients referred for prostate biopsy: combining detection in urine and needle rinse material.World journal of urology · 2015Article
- Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2.Oncogene · 2014Article
- Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element.Molecular endocrinology (Baltimore, Md.) · 2013Article
- Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.Neoplasia (New York, N.Y.) · 2013Article
- Recurrent gene fusions in prostate cancer: their clinical implications and uses.Current urology reports · 2013Review
- Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.Prostate cancer and prostatic diseases · 2013Article
- Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease.The American journal of pathology · 2012Article
- ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer.Virchows Archiv : an international journal of pathology · 2012Article
- ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.Prostate cancer and prostatic diseases · 2012Article
- The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.Human pathology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
Abstract
objectivesTo interrogate multifocal prostate cancer (PCa) to determine its predilection for metastasis, using ERG rearrangement as marker of clonality. A hallmark of PCa is that distinct tumor foci may arise independently, which has important biological and clinical implications. Recent studies characterizing ERG-rearranged PCa possessing intrafocal homogeneity but interfocal heterogeneity support this hypothesis.
methodsWe studied 26 patients who underwent prostatectomy and lymphadenectomy with at least 2 distinct PCa foci and 1 lymph node (LN) metastasis. Each focus was assessed for size, Gleason score, ERG rearrangement, and TMPRSS2-ERG transcript.
resultsFifteen of 26 cases exhibited interfocal homogeneity with regard to ERG rearrangement (ie, presence vs absence of ERG rearrangement). ERG rearrangement was present in all foci for 6 and absent in all foci for 9 cases. Two cases revealed interfocal heterogeneity with regard to rearrangement mechanism (ie, rearrangement through insertion or deletion). Eight of 26 cases revealed interfocal heterogeneity with regard to rearrangement status. In all cases with at least 1 ERG rearranged focus, we found the corresponding LN metastasis harboring an ERG rearrangement. Interestingly, in a subset of cases the rearrangement status in the LN did not correspond to size or Gleason score. All but 2 ERG rearranged foci had detectable TMPRSS2-ERG transcript levels.
conclusionsWhen multifocal PCa demonstrates both ERG-positive and ERG-negative foci, the positive foci have a greater predilection for metastasis. Larger studies are needed to confirm the potential additional risk an ERG rearranged focus confers on the likelihood of disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.